EP0604624A4 - Multimere formen von rezeptorprotein des humanen rhinovirus. - Google Patents

Multimere formen von rezeptorprotein des humanen rhinovirus.

Info

Publication number
EP0604624A4
EP0604624A4 EP93915452A EP93915452A EP0604624A4 EP 0604624 A4 EP0604624 A4 EP 0604624A4 EP 93915452 A EP93915452 A EP 93915452A EP 93915452 A EP93915452 A EP 93915452A EP 0604624 A4 EP0604624 A4 EP 0604624A4
Authority
EP
European Patent Office
Prior art keywords
receptor protein
human rhinovirus
multimeric forms
rhinovirus receptor
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915452A
Other languages
English (en)
French (fr)
Other versions
EP0604624A1 (de
Inventor
Jeffrey M Greve
Alan Mcclelland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of EP0604624A1 publication Critical patent/EP0604624A1/de
Publication of EP0604624A4 publication Critical patent/EP0604624A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/095—Rhinovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP93915452A 1992-06-22 1993-06-22 Multimere formen von rezeptorprotein des humanen rhinovirus. Withdrawn EP0604624A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90306992A 1992-06-22 1992-06-22
US903069 1992-06-22
PCT/US1993/005972 WO1994000485A1 (en) 1992-06-22 1993-06-22 Multimeric forms of human rhinovirus receptor protein

Publications (2)

Publication Number Publication Date
EP0604624A1 EP0604624A1 (de) 1994-07-06
EP0604624A4 true EP0604624A4 (de) 1997-03-12

Family

ID=25416893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915452A Withdrawn EP0604624A4 (de) 1992-06-22 1993-06-22 Multimere formen von rezeptorprotein des humanen rhinovirus.

Country Status (10)

Country Link
EP (1) EP0604624A4 (de)
JP (1) JPH06510208A (de)
KR (1) KR950702576A (de)
AU (1) AU675441B2 (de)
CA (1) CA2116109A1 (de)
FI (1) FI946006A0 (de)
HU (1) HUT75827A (de)
NO (1) NO944966L (de)
RU (1) RU94046450A (de)
WO (1) WO1994000485A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
GB9520641D0 (en) * 1995-10-10 1995-12-13 Medical Res Council Improvements in or relating to protection against intracellular infection
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
JP6431476B2 (ja) * 2012-03-31 2018-11-28 アール−ファーム・インターナショナル・リミテッド・ライアビリティ・カンパニーＲ−Ｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｌｌｃ オステオプロテゲリン由来の組成物およびその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365837A2 (de) * 1988-09-28 1990-05-02 Dana Farber Cancer Institute Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
EP0387701A1 (de) * 1989-03-09 1990-09-19 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von interzellularen Adhäsions-Molekülen und deren Bindungsliganden bei der Behandlung von Asthma
EP0468257A1 (de) * 1990-07-20 1992-01-29 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365837A2 (de) * 1988-09-28 1990-05-02 Dana Farber Cancer Institute Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
EP0387701A1 (de) * 1989-03-09 1990-09-19 Boehringer Ingelheim Pharmaceuticals Inc. Verwendung von interzellularen Adhäsions-Molekülen und deren Bindungsliganden bei der Behandlung von Asthma
EP0468257A1 (de) * 1990-07-20 1992-01-29 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREVE J. M. ET AL.,: "Mechanism of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1", J. VIROLOGY, vol. 65, November 1991 (1991-11-01), pages 6015 - 6023, XP000615280 *
MARTIN S. ET AL.,: "Erfolgreiche Blockade von Rhinovirusinfektionen durch ICAM-1-Immunglobulinchimäre in vitro", MEDIZINISCHE KLINIK, vol. 88, no. 4, 15 April 1993 (1993-04-15), pages 193 - 197, XP000615274 *
See also references of WO9400485A1 *

Also Published As

Publication number Publication date
AU675441B2 (en) 1997-02-06
EP0604624A1 (de) 1994-07-06
KR950702576A (ko) 1995-07-29
FI946006L (fi) 1994-12-21
WO1994000485A1 (en) 1994-01-06
HU9403720D0 (en) 1995-02-28
RU94046450A (ru) 1996-10-10
FI946006A7 (fi) 1994-12-21
JPH06510208A (ja) 1994-11-17
AU4543293A (en) 1994-01-24
NO944966D0 (no) 1994-12-21
HUT75827A (en) 1997-05-28
NO944966L (no) 1994-12-21
FI946006A0 (fi) 1994-12-21
CA2116109A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
ZA889033B (en) Vectors and compounds for direct expression of activated human protein c.
FI935175A0 (fi) Tyrosinkinas- HER4-humanreceptor
HUT70272A (en) Recombinant antibodies for human therapy
IL123447A0 (en) Recombinant anti-CD4 antibodies for human therapy
IL106278A0 (en) Bone formation-inducing protein
GB9215540D0 (en) Protein expression system
FI913470L (fi) Multimer form av receptorprotein hos humant rhinovirus.
EP0832125A4 (de) Menschlicher g-proteinrezeptor hgber32
GB9215541D0 (en) Protein expression system
HUT75827A (en) Multimeric forms of human rhinovirus receptor protein
EP0999848A4 (de) Chimäre proteine zur behandlung von diabetes
PL324822A1 (en) Human protein mp52 arg
NZ320450A (en) Control of whitefly using optionally substituted chlorophenyls
ZA896820B (en) Human rhinovirus peptides
IL105549A0 (en) Human glutamate receptor proteins and associated dna compounds
AU2444692A (en) Human substance p receptor
GB9215550D0 (en) Protein expression system
AU7174696A (en) Multimeric forms of human rhinovirus receptor protein
AU652567C (en) Multimeric form of human rhinovirus receptor protein
EP0674003A3 (de) Proteine die menschliche CNS Rezeptoren modulieren.
EP0787795A4 (de) Proteinvariante der menschlichen dna-topoisomerase
IL105307A0 (en) Serotonin receptor protein and related dna compounds
ZA925615B (en) Recombinant antibodies for human therapy
IE892805L (en) Human rhinovirus receptor protein
GB9304708D0 (en) Human neurokinin-3 receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 19970127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011222